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Editorial on the Research Topic
Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic
Applications
INTRODUCTION
γδT cells have been characterized by the expression of a γδT cell receptor (TCR).When the γδTCR
and the corresponding αβ TCR were first discovered it was assumed that the corresponding cell
types were likely to be functionally very similar. However, some 30 years later, we have realized that
they are not. Unlike αβ T cells, γδ T cells (i) sense target antigens independent of MHC molecules;
(ii) display NK-cell like innate reactivities, including killing of infected cells as well as microbes;
(iii) are able to take up large particulates, including bacteria, and (iv) can act as professional antigen
presenting cells.
The “stress sensing” abilities of γδ T cells have led to a great interest in exploring their potential
use in novel immunotherapies, not least in cancer. In addition, their capacity to produce various
cytokines and to interact with other cells, such as lymphocytes, myeloid cells, and neutrophils,
has raised an interest in their potential therapeutic use as immunomodulators. γδ T cells have
therefore recently come to stand out as a distinctly unique cell type. At the same time, we have
come to realize that γδ T cells are likely to be an ancient cell type with ancestors as far back as in
our common ancestors to jawless fish and thereby, potentially predating the development of our
adaptive immune system.
It is clear that to make full use of the great potential of γδ T cells in immunotherapeutic
interventions, we must significantly improve our understanding of the extensive plasticity and
multifunctionality of γδ T cells and of how these cells can be harnessed therapeutically, both safely
and effectively.
This Research Topic, contains 26 articles which includes Review, Original Research, and
Methods articles in the area of γδ T cell plasticity and multifunctionality, As shortly overviewed
in this editorial, these articles shall not represent entire field of γδ T cell biology but primarily
focuses on how an increased knowledge in this area can be used and developed further toward
improved immunotherapeutic applications in cancer, infectious disease, autoimmunity, and other
immunity-related areas.
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γδ T CELLS AT BARRIERS
γδ T cells and other “non-conventional” T cells V-gene usage
of antigen-receptors often correlates with distinct developmental
and functional features. A prominent example is murine
dendritic epidermal γδ T cells (DETC). They carry a single
“canonical” γδ TCR and depend on the butyrophilin-like Skint-
1 molecule for development. Humans lack DETC as Skint-
1 is a pseudogene. The mini review of Sutoh et al. discusses
the evolution of the Skint-1 family and DETC like cells. They
identify two species with a functional Skint-1 gene, namely
cattle and the cynomolgous macaque, as species with skin γδ T
cells sharing some features with murine DETC. Interestingly, in
lamprey, VLRC-expressing cells (one of the three linages of VLR-
antigen-receptor expressing lymphocytes) localize to epithelia
and exhibit a dendritic morphology in the skin. This led to
the hypothesis that stress-sensing lymphocyte at body surfaces
provide an evolutionary advantage and might even have existed
in the ancestor of jawed- and jawless-vertebrates.
The interplay of DETC and dermal Vγ4 T cells during
wound healing is the focus of two papers by the group
of Li, Wang et al. and Li, Wu et al.. They review current
knowledge on this subject and provide an original research
paper which investigates how epidermal invasion of IL-17
producing dermal Vγ4 cells suppresses IGF-1 production
by DETC and wound healing via IL-23 and IL-1β
producing keratinocytes.
Cruz et al. provides a comprehensive review on immune
responses and pathophysiology of the human skin T cells.
Although their cellular composition is quite different from that
of mice, it is quite intriguing that many molecular players,
especially cytokines, may function similarly as in mouse models.
A challenge is now to understand the relative contribution
of the different T cell subsets, including γδ T cells, to
integrity of healthy skin and their function in pathological
conditions such as psoriasis, alopecia areata, type II diabetes
and melanoma.
The mini review of McCarthy and Eberl covers the two
major subsets of human γδ T cells in mucosal immunity
and inflammation: stress-responsive, partially resident Vδ1
lymphocytes and microbial phosphoantigens-sensing Vγ9Vδ2 T
cells. Both γδ T cell subsets activate other (resident) leukocytes
such as neutrophils and myeloid DCs or differentiate to
professional APC, as shown for phosphoantigen-activated
Vγ9Vδ2 T cells.
The authors discuss how in both situations γδ T cells help to
communicate their findings of stressed transformed and infected
cells as well as extracellular pathogens downstream to other
immune cells. They speculate how this leads to inflammatory
responses and T cell activation serving as the boundaries of our
insides and the environment and how this knowledge can be used
for development of new therapeutic strategies.
Reinhardt and Prinz, discuss the pathogenesis of various
forms of spondyloarthritis. Currently, first choice of Spondylitis
ankylosans treatment is non-steroidal anti-inflammatory drugs,
physiotherapy and anti-TNF but more recently genome wide
association studies and promising results with antibodies
targeting IL-17 suggest the involvement of IL-17, IL-22, and IL-
23. The authors develop a scenario in which enthesis-resident
cells sense directly or indirectly mechanical stress and various
innate T cells (e.g., MAIT cells or γδ T cells) and/or ILC3 and
promote joint inflammation by production of IL-17 and IL-22.
γδ T CELLS IN AUTOIMMUNITY AND
INFECTION
γδ T cells are abnormally regulated in some autoimmunities.
In an original research article Migalovich Sheikhet et al. show
that systemic sclerosis (SSc) γδ T cell subsets are differentially
regulated by cardiolipin and zoledronate as compared to healthy
donor (HC) γδ T cells. CD25+ γδ T cells were elevated
significantly in SSc patient blood compared to HC. The main
conclusions and take home messages of this study was that SSc
γδ T cell functional responses were abnormal when stimulated by
cardiolipin and phosphoantigens and that this may contribute to
fibrosis and immunosuppression, both hallmarks of this disease.
Whilst novel forms of cancer immunotherapies is one of the
dominating fields of current research and proposed uses of γδ T
cells in the clinic, most investigators in the field would agree that
γδ T cells, as indeed other parts of the immune system, evolved
to combat pathogens. It is in this spirit we have included three
articles in this section describing functional involvement of γδ T
cells in infectious diseases.
It is well-known that as HIV virus infect CD4+ T-cells, the
pool of T cells that are able to produce IL-17 are reduced.
γδ T-cells can recognize and kill cells that are infected with
virus, including cells infected with HIV virus. As γδ T cells,
and in particular Vδ1 γδ T cells, are also able to produce
IL-17, they therefore provide an alternative source for IL-17
production in AIDS. However, in an original research paper in
this section, Dunne et al. show that such Vδ1 γδ T cells in HIV
infected individuals are often exhausted. They show that this
exhaustion is likely to be mediated by either PD-1 induction or
by downregulation of CD3ε expression.
Malaria is caused by the protozoan parasite Plasmodium
sp. As malaria causes high mortality and morbidity on several
continents and no successful vaccine exists malaria research
should be a priority. In a review article in this section Howard
et al. summarize what is known about the participation of
Vγ9Vδ2 T cells in malaria immune system reactivity. It is well-
known that this γδ T cell subset is activated and expanded during
a primary Plasmodium infection, but not why and what functions
this expansion mediates. Following a review of what is known
about this subsets innate and adaptive functions, Howard et al.
speculate that this subset could serve an important role as an
adjuvant in new malaria vaccine formulations.
In an accompanying minireview, Hviid et al. summarize what
is known about the participation and possible functions of the
Vδ1 γδ T cell subset. They suggest that the more “adaptive”
immunological behavior of this subset, as compared to Vγ9Vδ2 T
cells, is very likely reflected in their participation in malaria
immune reactivity and that this could also be the case for other
γ/δ chain combinations other than Vγ9Vδ2.
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γδ T CELLS IN TUMOR IMMUNITY
Pioneering studies by Hayday and colleagues in a mouse model
of cutaneous carcinogenesis have firmly established an important
role of γδ T cells in immune surveillance (1). Subsequently, it has
been found that human γδ T lymphocytes display potent HLA-
unrestricted cytotoxicity in vitro against a variety of tumor cell
lines and have demonstrated efficacy in vivo when transferred
into immunodeficient mice xenografted with different types of
tumor cells.
Given their HLA non-restricted method of antigen
recognition, the role of γδ T cells in anti-tumor immunity
has stimulated great interest to explore their potential for cancer
immunotherapy. Interestingly, the production of endogenous
PAgs, such as IPP, can be pharmacologically manipulated by
aminobisphosphonates (N-BP), such as Zoledronate, which
inhibit FPPS, the downstream enzyme of the MVA pathway,
leading to accumulation of endogenous IPP and Vγ9Vδ2 T
cell activation.
Simões et al. summarize current knowledge on target cell
recognition of γδ human T cells. Antigens expressed by target
cells are (over) expressed in stressed or transformed cells. Many
of them are unknown and knowledge on the molecular basis
of their recognition by the γδ TCR is very limited. Vγ9Vδ2 T-
cells sense phosphoantigens, isoprenoid synthesis metabolites,
which accumulate as after administration of drugs (amino-
bisphosphonates), cell-transformation or microbial infections.
This sensing is mediated by the Vγ9Vδ2 TCR which “sees”
target cells after binding of the phosphoantigens to target
cell-expressed butyrophilin (BTN)3A1 molecule. BTN and
butyrophilin-like (BTNL) molecules mainly present on epithelial
and tumor cells regulate the homing and maturation of
certain γδ clonotypes. BTN3A1 is required for Vγ9Vδ2 T cell
recognition of PAgs and BTN3A1 modulation in vitro and in
vivo impacts on anti-tumor efficacy of γδ T cells (Blazquez
et al.), thus providing the potential for novel Vγ9Vδ2 T cell-based
cancer immunotherapy.
Activating NK cell receptors with NKG2D as most prominent
example, act either alone or by providing a co-stimulatory
signal to the γδ TCR. They serve also as stress-sensors since
expression of many NKG2D ligands results from cell-stress (2).
Similar to NK cells, γδ T-cells are endowed with anti-leukemia
and anti-infection potential and do not mediate graft-vs.-host
disease. These features are particularly useful in the setting of
HLA haploidentical HSCT depleted of αβ+ T and B lymphocytes
to cure high-risk acute leukemias (Pistoia et al.). In this setting,
high numbers of both γδ T cells (Vδ1 and Vδ2) are infused
together with CD34+ HSC and may contribute to rapid control
of infections and leukemia relapse. In addition, Zoledronate
potentiates the cytotoxic activity of γδ T cells in vitro and its
infusion in patients strongly promotes γδ T cell differentiation
and cytolytic activity. Hence, treatment with Zoledronate
may contribute to further improve the patient clinical
outcome after HLA-haploidentical HSCT depleted of αβ+ T
and B lymphocytes.
Intravenous application of Zoledronate together with low-
dose IL-2 has been evaluated as a means of in vivo activation of γδ
T cells in cancer patients. Hoeres et al. provide a comprehensive
review of established and newer strategies exploiting γδ T cells in
cancer immunotherapy.
Most likely, strategies aiming to activate γδ T cells in vivo
will have to be combined with other treatment regimens to
obtain optimal anti-tumor activity. Bhat et al. discuss the
current development of drugs targeting major pathways of
epigenetic regulation and their possible impact on γδ T cell
multifunctionality and develop concepts of how some of these
approaches might help to improve the efficacy of γδ T cell-based
cancer immunotherapy.
Additional strategies to improve the anti-tumor activity of γδ
T cells are under study.
These include the use of antibodies to trigger Fc receptor-
dependent ADCC, or the use of bispecific antibody
constructs to cross-link the γδ TCR with tumor cell
surface antigens. Varesano et al. have used the therapeutic
anti-EGF-R humanized mAb Cetuximab, in addition to
Zoledronate in order to enhance Vδ2 T cell-mediated killing
of cancer cells. For this purpose, they have employed a 3-D
culture system, consisting of colorectal cancer spheroids,
and have shown that Cetuximab triggers Zoledronate-
activated Vδ2 T cells to perform ADCC of colorectal
cancer and destroy spheroids. Thus, this 3-D system may
prove reliable to evaluate the whole anti-tumor effect of
combinatorial immunotherapies.
γδ T cells can be redirected to the cancer cell using antibodies.
This can be achieved, for instance by the use of bispecific
antibodies, in which one binding site recognizes a tumor specific
cell surface molecule and the other binding site recognizes
CD16 or CD3 or the Vγ9Vδ2 TCR; such bispecific antibodies
have shown efficacy in preclinical mouse models. Oberg et al.
employed the bispecific antibody HER2xCD16 in the form of
a “tribody” construct to redirect CD16 expressing γδ and NK
cells against HER2 positive tumor cell targets. Compared to
Trastuzumab, the HER2xCD16 tribody had superior efficacy in
promoting CD16-mediated γδ and NK killing of several types of
tumor cells expressing HER2 antigen.
Another approach to improve the efficacy of γδ T cell-
based cancer immunotherapy consists in the adoptive transfer
of genetically-modified T lymphocytes. This includes lentiviral-
mediated transduction of T cells with chimeric antigen receptors
(CARs) or with an exogenous TCR of known specificity.
To date, both approaches have utilized αβ T cells, but
γδ T cells may also be an appealing target. Here, Fisher
and Anderson provide a comprehensive review of current
engineering approaches in human γδ T cells for cancer
immunotherapy. Thus, a tumor-specific αβ TCR can be
introduced into γδ T cells without the risk of mispairing
between the endogenous and exogenous TCRs. It is also possible
to transduce peripheral T lymphocytes with a high-affinity
Vγ9Vδ2 TCR (Straetemans et al.). These engineered T cells,
named TEGs (T cells engineered to express a defined γδT cell
receptor), are broadly reactive against several different tumors
and have been produced under GMP conditions to enter a
Phase I clinical trial in patients with relapsed/refractory acute
myeloid leukemia.
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One of the basic observations supporting a role of γδ T
cells in tumor immune surveillance is their presence amongst
tumor-infiltrating lymphocytes (TIL) in most human tumors.
However, the clinical relevance of γδ TILs is unclear because
the relative frequencies of tumor-infiltrating γδ T cells correlate
with tumor remission, or with tumor progression or even fail to
correlate with prognosis. These findings are strongly suggestive
of the fact that γδ T cells in the tumor microenvironment
may play opposite functions and thus positive or negative
correlation with prognosis may depend on the specific γδ T
cell subset present at the tumor site (Pauza et al.). It is clear,
however, that an increased presence of γδ T cells within a
tumor per se is not necessarily associated with a beneficial
effect. As discussed here by Lo Presti et al., there are multiple
interactions of tumor-infiltrating γδ T cells within the local
tumor microenvironment that strongly influence the functional
outcome. Relevant factors include (but are not restricted to)
tumor-derived immunosuppressive cytokines and metabolites,
locally expressed inhibitory checkpoints such as PD-1 (Castella
et al.), myeloid-derived suppressor cells (MDSCs, Sacchi et al.)
and hypoxia (Siegers et al.). Hence, different conditions
occurring in the context of the tumor microenvironment may
inhibit γδ T cell functions or even convert γδ T cells into
suppressive cells, which negatively influence tumor outcome and
patient’s prognosis.
Therefore, it is a major challenge for future studies to
determine how to specifically boost the anti-tumor effects of γδ
T cells while simultaneously shunting their suppressive activity.
CONCLUDING REMARKS
After 30 years of γδ T cell research, it is clear that these cells
are intimately involved in the control of tissue homeostasis,
infection, and malignancy (Edelblum et al.). The identification
of specific ligands for the γδ TCR provides strong support
for the idea that γδ T cells are non-redundant to αβ T cells.
Apart from the detailed knowledge of their physiological and
pathophysiological significance, we are currently experiencing
new exciting developments aimed at bringing γδ T cells into
clinical medicine.
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